Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Hähnel, T; Baldow, C; Guilhot, J; Guilhot, F; Saussele, S; Mustjoki, S; Jilg, S; Jost, PJ; Dulucq, S; Mahon, FX; Roeder, I; Fassoni, AC; Glauche, I.
Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML.
Cancer Res. 2020; 80(11):2394-2406 Doi: 10.1158/0008-5472.CAN-19-2175
Web of Science PubMed FullText FullText_MUG


Co-Autor*innen der Med Uni Graz
Jost Philipp

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Recent clinical findings in patients with chronic myeloid leukemia (CML) suggest that the risk of molecular recurrence after stopping tyrosine kinase inhibitor (TKI) treatment substantially depends on an individual's leukemia-specific immune response. However, it is still not possible to prospectively identify patients that will remain in treatment-free remission (TFR). Here, we used an ordinary differential equation model for CML, which explicitly includes an antileukemic immunologic effect, and applied it to 21 patients with CML for whom BCR-ABL1/ABL1 time courses had been quantified before and after TKI cessation. Immunologic control was conceptually necessary to explain TFR as observed in about half of the patients. Fitting the model simulations to data, we identified patient-specific parameters and classified patients into three different groups according to their predicted immune system configuration ("immunologic landscapes"). While one class of patients required complete CML eradication to achieve TFR, other patients were able to control residual leukemia levels after treatment cessation. Among them were a third class of patients that maintained TFR only if an optimal balance between leukemia abundance and immunologic activation was achieved before treatment cessation. Model simulations further suggested that changes in the BCR-ABL1 dynamics resulting from TKI dose reduction convey information about the patient-specific immune system and allow prediction of outcome after treatment cessation. This inference of individual immunologic configurations based on treatment alterations can also be applied to other cancer types in which the endogenous immune system supports maintenance therapy, long-term disease control, or even cure. SIGNIFICANCE: This mathematical modeling approach provides strong evidence that different immunologic configurations in patients with CML determine their response to therapy cessation and that dose reductions can help to prospectively infer different risk groups.See related commentary by Triche Jr, p. 2083. ©2020 American Association for Cancer Research.
Find related publications in this database (using NLM MeSH Indexing)
Fusion Proteins, bcr-abl -
Humans -
Leukemia, Myelogenous, Chronic, BCR-ABL Positive -
Protein Kinase Inhibitors -
Recurrence -
Remission Induction -

© Med Uni Graz Impressum